Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

Presentation TCT 2017

SURTAVI Trial Critique and Unanswered Questions

Presenter: David J. Moliterno, Vinod H. Thourani, E. Murat Tuzcu

November 01, 2017

Presentation TCT 2017

SURTAVI: Topline Findings and Practice Implications

Presenter: David J. Moliterno, Vinod H. Thourani, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

Presenter: Steven R. Bailey, Patrick W. Serruys, Nicolas M. Van Mieghem

November 01, 2017

Presentation TCT 2017

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Presenter: Jean-Claude Laborde, Eric Van Belle, Lars Sondergaard

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

Presenter: Martin B. Leon, Patrick T. O'Gara, Nicolas M. Van Mieghem

October 30, 2017

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

Shelley Wood

August 27, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

Advertisement

SURTAVI Trial Critique and Unanswered Questions

SURTAVI: Topline Findings and Practice Implications

TCT 107: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Complete 1-Year Outcomes From the SURTAVI Trial

TCT 39: Clinical Outcomes in SURTAVI Based on Revascularization Stratification

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Featured Lecture: Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients : Complete 1-Year Outcomes from the SURTAVI Trial

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

TCTMD’s Top 10 Most Popular Stories for July 2017

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

SURTAVI Vignette I: Applying Bayesian Methodology to Interventional Clinical Trials

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

More Early Stroke With SAVR Than TAVR in SURTAVI

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content